- Home
- ONDS vs CELC Comparison
ONDS vs CELC Comparison
Compare ONDS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONDS | CELC |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ONDS | CELC |
|---|---|---|
| Price | $8.54 | $102.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $10.00 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 76.5M | 870.9K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,748,922.00 | N/A |
| Revenue This Year | $417.68 | N/A |
| Revenue Next Year | $244.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 208.40 | N/A |
| 52 Week Low | $0.57 | $7.58 |
| 52 Week High | $11.70 | $112.64 |
Technical Indicators
Market Signals| Indicator | ONDS | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 59.89 |
| Support Level | $8.67 | $97.27 |
| Resistance Level | $9.84 | $103.50 |
| Average True Range (ATR) | 0.91 | 4.47 |
| MACD | -0.01 | -1.13 |
| Stochastic Oscillator | 47.48 | 31.23 |
Price Performance
Historical ComparisonAbout ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.